| 5.7171 0.007 (0.12%) | 12-05 10:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.28 | 1-year : | 8.51 |
| Resists | First : | 6.23 | Second : | 7.28 |
| Pivot price | 5.28 |
|||
| Supports | First : | 5.43 | Second : | 4.92 |
| MAs | MA(5) : | 5.6 |
MA(20) : | 5.29  |
| MA(100) : | 4.92 |
MA(250) : | 0 | |
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 84.5 |
D(3) : | 84.5 |
| RSI | RSI(14): 62.5 |
|||
| 52-week | High : | 6.67 | Low : | 3.38 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ MNKD ] has closed below upper band by 11.4%. Bollinger Bands are 9.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.81 - 5.84 | 5.84 - 5.86 |
| Low: | 5.51 - 5.54 | 5.54 - 5.57 |
| Close: | 5.66 - 5.71 | 5.71 - 5.75 |
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
Thu, 04 Dec 2025
Insider Selling: Michael Castagna Sells Shares of MannKind Corp (MNKD) - GuruFocus
Thu, 04 Dec 2025
Mannkind CEO Castagna sells $601k in shares - Investing.com
Wed, 03 Dec 2025
MannKind's ReadyFlow Autoinjector: A Game Changer For Heart Failure Patients (NASDAQ:MNKD) - Seeking Alpha
Tue, 02 Dec 2025
MAI Capital Management Reduces Stock Holdings in MannKind Corporation $MNKD - MarketBeat
Mon, 01 Dec 2025
MannKind (MNKD) Awaits FDA Decision on Furoscix Autoinjector - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 307 (M) |
| Shares Float | 301 (M) |
| Held by Insiders | 1.7 (%) |
| Held by Institutions | 56.9 (%) |
| Shares Short | 21,930 (K) |
| Shares Short P.Month | 25,160 (K) |
| EPS | 0.1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.15 |
| Profit Margin | 9.3 % |
| Operating Margin | 22.8 % |
| Return on Assets (ttm) | 9.9 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 17.2 % |
| Gross Profit (p.s.) | 0.76 |
| Sales Per Share | 1.02 |
| EBITDA (p.s.) | 0.27 |
| Qtrly Earnings Growth | -35 % |
| Operating Cash Flow | 49 (M) |
| Levered Free Cash Flow | 29 (M) |
| PE Ratio | 56.95 |
| PEG Ratio | 0 |
| Price to Book value | -40.68 |
| Price to Sales | 5.57 |
| Price to Cash Flow | 35.79 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|